SCHEMBL3619294

SCHEMBL3619294

CC(Cc1ccccc1)[C@H](N)CO

nearest known ligand 0.68

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 3/20 0.68
CYP2D6 P10635 1/20 0.64
TAAR1 Q96RJ0 3/20 0.57
SLC6A2 P23975 2/20 0.57
MAOA P21397 1/20 0.57
SLC6A4 P31645 1/20 0.57
SLC6A3 Q01959 1/20 0.57
SIGMAR1 Q99720 1/20 0.57
CYP2A6 P11509 1/20 0.57
ADORA2A P29274 1/20 0.57
ADORA1 P30542 1/20 0.57
EPHX1 P07099 1/20 0.50
ALPI P09923 1/20 0.47
PKM P14618 1/20 0.47
PTGS1 P23219 1/20 0.47
XIAP P98170 1/20 0.47
SLC7A5 Q01650 1/20 0.47
LAP3 P28838 3/20 0.44
ANPEP P15144 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3619292 1.00 TRPA1 (0.68) TRPA1CYP2D6TAAR1SLC6A2MAOA
SCHEMBL30758601 0.86 TRPA1 (0.70) TRPA1CYP2D6TAAR1SLC6A2MAOA
SCHEMBL30758604 0.86 TRPA1 (0.70) TRPA1CYP2D6TAAR1SLC6A2MAOA
SCHEMBL28183527 0.82 CYP2D6 (0.67) TRPA1CYP2D6TAAR1SLC6A2MAOA
SCHEMBL15101101 0.81 TRPA1 (1.00) TRPA1CYP2D6TAAR1SLC6A2MAOA
Hydrochloric Acid SCHEMBL17710431 0.80 CYP2D6 (0.64) TRPA1CYP2D6TAAR1SLC6A2MAOA
SCHEMBL4981489 0.79 CYP2D6 (0.58) TRPA1CYP2D6TAAR1SLC6A2MAOA
SCHEMBL1396351 0.79 CYP2D6 (0.69) TRPA1CYP2D6TAAR1SLC6A2MAOA
SCHEMBL23869573 0.79 CYP2D6 (1.00) TRPA1CYP2D6TAAR1SLC6A2MAOA
Alcohol SCHEMBL6562414 0.79 TRPA1 (0.79) TRPA1CYP2D6TAAR1SLC6A2MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2114906-B1 2-AMINOOXAZOLINES AS TAAR1 LIGANDS FOR CNS DISORDERS HOFFMANN LA ROCHE (CH) 2014-08-06 EP disclosed
US-8604061-B2 2-aminooxazolines as TAAR1 ligands HOFFMANN-LA ROCHE INC. (US) 2013-12-10 US disclosed
US-20120196903-A1 2-AMINOOXAZOLINES AS TAAR1 LIGANDS GALLEY GUIDO (DE) 2012-08-02 US disclosed
US-20100120864-A1 2-AMINOOXAZOLINES AS TAAR1 LIGANDS GALLEY GUIDO 2010-05-13 US disclosed
US-20080261920-A1 2-Aminooxazolines as TAAR1 ligands F. HOFFMANN-LA ROCHE AG (CH) 2008-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100120864-A1 2-AMINOOXAZOLINES AS TAAR1 LIGANDS TAAR1, TAAR5, NPY2R TRPA1 261/4885CYP2D6 968/4885TAAR1 1/4885
US-20120196903-A1 2-AMINOOXAZOLINES AS TAAR1 LIGANDS TAAR1, TAAR5, NPY2R TRPA1 326/4885CYP2D6 908/4885TAAR1 1/4885
US-20080261920-A1 2-Aminooxazolines as TAAR1 ligands TAAR1, TAAR5, NPY2R TRPA1 261/4885CYP2D6 968/4885TAAR1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.